Close Menu

UPenn

Using baseline blood samples, researchers have identified an eight-gene expression signature to predict patient responses to Zytiga plus prednisone or Xtandi.

The agreement will facilitate key proof-of-concept studies for Hemogenyx's HEMO-CAR-T product in AML, where there is an unmet need for new safe and effective treatments.

The analysis suggested CDK7 inhibitors could boost the sensitivity of tumor cells capable of homologous recombination to PARP inhibitor treatment.

Results show population screening can pick up risky BRCA1/2 mutations in men and women from Ashkenazi Jewish populations in the US, though engagement challenges remain.

The field is collecting evidence supporting genomics-guided care but experts are still awaiting prospective data and grappling with other challenges.

Presentations at the American Society of Clinical Oncology's virtual annual meeting included new findings relevant to both blood- and spinal fluid-based approaches.

Additional analyses found the talazoparib arm reported a better quality of life and a limited effect of broader tumor genomic markers on clinical benefit or progression-free survival.

With EMR upgrades, Penn and Rush now have structured genomic data informing clinical decision support in their precision oncology programs, but much work remains.

The phase III trial saw significant overall survival and remission rates in relapsed or treatment refractory acute myeloid leukemia cases treated with the FLT3 inhibitor gilteritinib.

A modified analogue of rucaparib is being used to track PARP-1 expression in PARP inhibitor-treated patients with pancreatic, breast, prostate, and other cancer types.

Pages